Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 6.39 USD 6.15%
Market Cap: 943m USD
Have any thoughts about
Adaptive Biotechnologies Corp?
Write Note

Adaptive Biotechnologies Corp
Income to Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adaptive Biotechnologies Corp
Income to Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income to Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Income to Minority Interest
$104k
CAGR 3-Years
1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Income to Minority Interest
$14m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Danaher Corp
NYSE:DHR
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Agilent Technologies Inc
NYSE:A
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Adaptive Biotechnologies Corp
Glance View

Market Cap
942.9m USD
Industry
Life Sciences Tools & Services

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

ADPT Intrinsic Value
6.94 USD
Undervaluation 8%
Intrinsic Value
Price

See Also

What is Adaptive Biotechnologies Corp's Income to Minority Interest?
Income to Minority Interest
104k USD

Based on the financial report for Sep 30, 2024, Adaptive Biotechnologies Corp's Income to Minority Interest amounts to 104k USD.

What is Adaptive Biotechnologies Corp's Income to Minority Interest growth rate?
Income to Minority Interest CAGR 3Y
1%

Over the last year, the Income to Minority Interest growth was 49%. The average annual Income to Minority Interest growth rates for Adaptive Biotechnologies Corp have been 1% over the past three years .

Back to Top